ACHL
Achilles Therapeutics PLC ADR
NASDAQ: ACHL · HEALTHCARE · BIOTECHNOLOGY
$1.48
+0.00% today
Updated 2026-04-29
Market cap
$63.22M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.66
Dividend yield
—
52W range
$0 – $0
Volume
1.2M
Achilles Therapeutics PLC ADR (ACHL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | — | $303250.00 | $778005.00 | $3.29M | $3.69M | $4.73M |
| Gross profit | — | $-303250.00 | $-778005.00 | $-3.29M | $-3.69M | $-4.73M |
| Gross margin | — | — | — | — | — | — |
| R&D | $4.80M | $9.07M | $22.63M | $42.22M | $57.26M | $67.65M |
| SG&A | $2.10M | $4.70M | $11.10M | $21.97M | $21.12M | $17.01M |
| Operating income | $-6.90M | $-13.78M | $-33.73M | $-64.19M | $-78.38M | $-75.25M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-6.73M | $-13.47M | $-32.95M | $-57.77M | $-78.38M | $-70.44M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-6.90M | $-13.78M | $-33.73M | $-61.05M | $-82.07M | $-75.17M |
| Interest expense | $0.00 | $215000.00 | $531000.00 | $3.13M | $7.32M | — |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-6.89M | $-13.99M | $-33.20M | $-61.10M | $-71.18M | $-69.67M |
| Net income growth (YoY) | — | -103.1% | -137.3% | -84.0% | -16.5% | +2.1% |
| Profit margin | — | — | — | — | — | — |